Vaccine Potential of Nipah Virus-Like Particles

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Walpita, Pramila ^a   Barr, Jennifer ^b   Sherman, Michael ^a   Basler, Christopher F ^c   Wang, Linfa ^b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b CSIRO   (Australia)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN F; PROTEIN G; PROTEIN M; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE; GLYCOPROTEIN; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BIOCHEMICAL COMPOSITION; CONTROLLED STUDY; CRYOELECTRON MICROSCOPY; EMBRYO; FEMALE; GENE ACTIVATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOREACTIVITY; INNATE IMMUNITY; MOUSE; NIPAH VIRUS; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRUCTURAL HOMOLOGY; VIRUS LIKE AGENT; VIRUS MORPHOLOGY; ANIMAL; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; CELL STRAIN HEK293; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; GIANT CELL; IMMUNOLOGY; METABOLISM; PLASMID; SPECIES DIFFERENCE; ULTRASTRUCTURE; VIRION; VIROLOGY;

ANIMALIA; MEASLES VIRUS; MUS; NIPAH VIRUS; PARAMYXOVIRIDAE; SUIDAE;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GIANT CELLS; GLYCOPROTEINS; HEK293 CELLS; HUMANS; IMMUNITY, INNATE; MICE; MICE, INBRED BALB C; NIPAH VIRUS; PLASMIDS; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY; TRANSCRIPTION, GENETIC; TRANSFECTION; VIRAL PROTEINS; VIRAL VACCINES; VIRION;

EID: 79953756717     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018437     Document Type: Article

References (77)

1. Chan KP, Rollin PE, Ksiazek TG, Leo YS, Goh KT, et al. (2002) A survey of Nipah virus infection among various risk groups in Singapore. Epidemiol Infect 128: 93-98.
2. Chua KB, Goh KJ, Wong KT, Kamarulzaman A, Tan PS, et al. (1999) Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 354: 1257-1259.
3. Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, et al. (2000) Nipah virus: a recently emergent deadly paramyxovirus. Science 288: 1432-1435.
4. Chua KB, (2003) Nipah virus outbreak in Malaysia. J Clin Virol 26: 265-275.
5. Chadha MS, Comer JA, Lowe L, Rota PA, Rollin PE, et al. (2006) Nipah virus-associated encephalitis outbreak, Siliguri, India. Emerg Infect Dis 12: 235-240.
6. Hsu VP, Hossain MJ, Parashar UD, Ali MM, Ksiazek TG, et al. (2004) Nipah virus encephalitis reemergence, Bangladesh. Emerg Infect Dis 10: 2082-2087.
7. ICDDR BCfhapr (2004) Nipah encephalitis outbreak over wide area in western Bangladesh. Health and Science Bulletin 2: 7-11.
8. WHO, (2004) Nipah virus outbreak(s) in Bangladesh. The Weekly Epidemiological Record (WER) 79: 168-171.
9. ICDDR BCfhapr (2005) Nipah virus outbreak from date palm juice. Health and Science Bulletin 3: 1-5.
10. Gurley ES, Montgomery JM, Hossain MJ, Bell M, Azad AK, et al. (2007) Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg Infect Dis 13: 1031-1037.
11. Gurley ES, Montgomery JM, Hossain MJ, Islam MR, Molla MA, et al. (2007) Risk of nosocomial transmission of Nipah virus in a Bangladesh hospital. Infect Control Hosp Epidemiol 28: 740-742.
12. ICDDR BCfhapr (2004) Person-to-person transmission of Nipah virus during outbreak in Faridpur District. Health and Science Bulletin 2: 5-9.
13. Lam SK, (2003) Nipah virus-a potential agent of bioterrorism? Antiviral Res 57: 113-119.
14. Eaton BT, Broder CC, Middleton D, Wang LF, (2006) Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol 4: 23-35.
15. Harcourt BH, Tamin A, Ksiazek TG, Rollin PE, Anderson LJ, et al. (2000) Molecular characterization of Nipah virus, a newly emergent paramyxovirus. Virology 271: 334-349.
16. Harcourt BH, Lowe L, Tamin A, Liu X, Bankamp B, et al. (2005) Genetic characterization of Nipah virus, Bangladesh, 2004. Emerg Infect Dis 11: 1594-1597.
17. Wang L, Harcourt BH, Yu M, Tamin A, Rota PA, et al. (2001) Molecular biology of Hendra and Nipah viruses. Microbes Infect 3: 279-287.
18. Wong KT, Shieh WJ, Kumar S, Norain K, Abdullah W, et al. (2002) Nipah virus infection: pathology and pathogenesis of an emerging paramyxoviral zoonosis. Am J Pathol 161: 2153-2167.
19. Bossart KN, McEachern JA, Hickey AC, Choudhry V, Dimitrov DS, et al. (2007) Neutralization assays for differential henipavirus serology using Bio-Plex protein array systems. J Virol Methods 142: 29-40.
20. Ciancanelli MJ, Basler CF, (2006) Mutation of YMYL in the Nipah virus matrix protein abrogates budding and alters subcellular localization. J Virol 80: 12070-12078.
21. Bonaparte MI, Dimitrov AS, Bossart KN, Crameri G, Mungall BA, et al. (2005) Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci U S A 102: 10652-10657.
22. Negrete OA, Levroney EL, Aguilar HC, Bertolotti-Ciarlet A, Nazarian R, et al. (2005) EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature 436: 401-405.
23. Negrete OA, Wolf MC, Aguilar HC, Enterlein S, Wang W, et al. (2006) Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus. PLoS Pathog 2: e7.
24. Schmitt AP, Lamb RA, (2004) Escaping from the cell: assembly and budding of negative-strand RNA viruses. Curr Top Microbiol Immunol 283: 145-196.
25. Takimoto T, Portner A, (2004) Molecular mechanism of paramyxovirus budding. Virus Res 106: 133-145.
26. Weingartl HM, Berhane Y, Caswell JL, Loosmore S, Audonnet JC, et al. (2006) Recombinant nipah virus vaccines protect pigs against challenge. J Virol 80: 7929-7938.
27. Pantaleo G, Esteban M, Jacobs B, Tartaglia J, (2010) Poxvirus vector-based HIV vaccines. Curr Opin HIV AIDS 5: 391-396.
28. McEachern JA, Bingham J, Crameri G, Green DJ, Hancock TJ, et al. (2008) A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats. Vaccine 26: 3842-3852.
29. Mungall BA, Middleton D, Crameri G, Bingham J, Halpin K, et al. (2006) Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol 80: 12293-12302.
30. Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, et al. (1993) The influence of antigen organization on B cell responsiveness. Science 262: 1448-1451.
31. Jennings GT, Bachmann MF, (2007) Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr Mol Med 7: 143-155.
32. Noad R, Roy P, (2003) Virus-like particles as immunogens. Trends Microbiol 11: 438-444.
33. Defang GN, Khetawat D, Broder CC, Quinnan GV Jr, (2010) Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system. Vaccine 29: 212-220.
34. Chattopadhyay A, Rose JK, (2010) Complementing defective viruses expressing separate paramyxovirus glycoproteins provide a new vaccine vector approach. J Virol.
35. Johnson JE, Nasar F, Coleman JW, Price RE, Javadian A, et al. (2007) Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 360: 36-49.
36. Jegerlehner A, Tissot A, Lechner F, Sebbel P, Erdmann I, et al. (2002) A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20: 3104-3112.
37. Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, et al. (2010) A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med 16: 334-338.
38. Chackerian B, (2007) Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 6: 381-390.
39. Grgacic EV, Anderson DA, (2006) Virus-like particles: passport to immune recognition. Methods 40: 60-65.
40. Jennings GT, Bachmann MF, (2008) The coming of age of virus-like particle vaccines. Biol Chem 389: 521-536.
41. Jennings GT, Bachmann MF, (2009) Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol 49: 303-326.
42. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, et al. (2007) Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 196 (Suppl 2): S430-437.
43. Coronel EC, Murti KG, Takimoto T, Portner A, (1999) Human parainfluenza virus type 1 matrix and nucleoprotein genes transiently expressed in mammalian cells induce the release of virus-like particles containing nucleocapsid-like structures. J Virol 73: 7035-7038.
44. Pantua HD, McGinnes LW, Peeples ME, Morrison TG, (2006) Requirements for the assembly and release of Newcastle disease virus-like particles. J Virol 80: 11062-11073.
45. Schmitt AP, Leser GP, Waning DL, Lamb RA, (2002) Requirements for budding of paramyxovirus simian virus 5 virus-like particles. J Virol 76: 3952-3964.
46. Sugahara F, Uchiyama T, Watanabe H, Shimazu Y, Kuwayama M, et al. (2004) Paramyxovirus Sendai virus-like particle formation by expression of multiple viral proteins and acceleration of its release by C protein. Virology 325: 1-10.
47. Teng MN, Collins PL, (1998) Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles. J Virol 72: 5707-5716.
48. Patch JR, Crameri G, Wang LF, Eaton BT, Broder CC, (2007) Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein. Virol J 4: 1.
49. McGinnes LW, Pantua H, Laliberte JP, Gravel KA, Jain S, et al. (2010) Assembly and biological and immunological properties of Newcastle disease virus-like particles. J Virol 84: 4513-4523.
50. Bossart KN, Crameri G, Dimitrov AS, Mungall BA, Feng YR, et al. (2005) Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol 79: 6690-6702.
51. Bossart KN, Wang LF, Flora MN, Chua KB, Lam SK, et al. (2002) Membrane fusion tropism and heterotypic functional activities of the Nipah virus and Hendra virus envelope glycoproteins. J Virol 76: 11186-11198.
52. Lamb RA, Kolakofsky, D, (2001) Paramyxoviridae: the viruses and their replication. In: Knipe PMH DM, Griffin DE, Martin MA, Lamb RA, Roizman B, Straus SE, editors. Fields virology. 4th ed Philadelphia, PA Lippincott, Williams & Wilkins pp. 1305-1340.
53. Plotkin SA, (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17: 1055-1065.
54. Reading SA, Dimmock NJ, (2007) Neutralization of animal virus infectivity by antibody. Arch Virol 152: 1047-1059.
55. Guillaume V, Contamin H, Loth P, Grosjean I, Courbot MC, et al. (2006) Antibody prophylaxis and therapy against Nipah virus infection in hamsters. J Virol 80: 1972-1978.
56. Niwa H, Yamamura K, Miyazaki J, (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-199.
57. Walpita P, Peters CJ, (2007) Cis-acting elements in the antigenomic promoter of Nipah virus. J Gen Virol 88: 2542-2551.
58. Lokugamage KG, Yoshikawa-Iwata N, Ito N, Watts DM, Wyde PR, et al. (2008) Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. Vaccine 26: 797-808.
59. Pattnaik AK, Wertz GW, (1991) Cells that express all five proteins of vesicular stomatitis virus from cloned cDNAs support replication, assembly, and budding of defective interfering particles. Proc Natl Acad Sci U S A 88: 1379-1383.
60. Whelan SP, Wertz GW, (1999) The 5′ terminal trailer region of vesicular stomatitis virus contains a position-dependent cis-acting signal for assembly of RNA into infectious particles. J Virol 73: 307-315.
61. Sherman MB, Weaver SC, (2010) Structure of the recombinant alphavirus Western equine encephalitis virus revealed by cryoelectron microscopy. J Virol 84: 9775-9782.
62. Walpita P, Flick R, (2005) Reverse genetics of negative-stranded RNA viruses: a global perspective. FEMS Microbiol Lett 244: 9-18.
63. Goldsmith CS, Whistler T, Rollin PE, Ksiazek TG, Rota PA, et al. (2003) Elucidation of Nipah virus morphogenesis and replication using ultrastructural and molecular approaches. Virus Res 92: 89-98.
64. Hyatt AD, Zaki SR, Goldsmith CS, Wise TG, Hengstberger SG, (2001) Ultrastructure of Hendra virus and Nipah virus within cultured cells and host animals. Microbes Infect 3: 297-306.
65. Pager CT, (2006) A mature and fusogenic form of Nipah virus F protein requires proteolytic. Virology 346: 251-257.
66. Beutler BA, (2009) TLRs and innate immunity. Blood 113: 1399-1407.
67. Iwasaki A, Medzhitov R, (2010) Regulation of adaptive immunity by the innate immune system. Science 327: 291-295.
68. Mao CP, Hung CF, Kang TH, He L, Tsai YC, et al. (2010) Combined administration with DNA encoding vesicular stomatitis virus G protein enhances DNA vaccine potency. J Virol 84: 2331-2339.
69. Bratt MA, Gallaher WR, (1969) Preliminary analysis of the requirements for fusion from within and fusion from without by Newcastle disease virus. Proc Natl Acad Sci U S A 64: 536-543.
70. Collins SE, Noyce RS, Mossman KL, (2004) Innate cellular response to virus particle entry requires IRF3 but not virus replication. J Virol 78: 1706-1717.
71. Gilbert JM, Greenberg HB, (1997) Virus-like particle-induced fusion from without in tissue culture cells: role of outer-layer proteins VP4 and VP7. J Virol 71: 4555-4563.
72. Clavel F, Charneau P, (1994) Fusion from without directed by human immunodeficiency virus particles. J Virol 68: 1179-1185.
73. Knutton S, Jackson D, Ford M, (1977) Studies of membrane fusion. I. Paramyxovirus-induced cell fusion, a scanning electron-microscope study. J Cell Sci 28: 179-188.
74. Guillaume V, Contamin H, Loth P, Georges-Courbot MC, Lefeuvre A, et al. (2004) Nipah virus: vaccination and passive protection studies in a hamster model. J Virol 78: 834-840.
75. Iwasaki A, Medzhitov R, (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5: 987-995.
76. Lo MK, Miller D, Aljofan M, Mungall BA, Rollin PE, et al. (2010) Characterization of the antiviral and inflammatory responses against Nipah virus in endothelial cells and neurons. Virology 404: 78-88.
77. Wong KT, (2003) A golden hamster model for human acute Nipah virus infection. Am J pathol 5: 2127-2137.